Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05384405
Other study ID # TMS20220425
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 1, 2022
Est. completion date February 28, 2025

Study information

Verified date April 2024
Source Central South University
Contact Renrong Wu, M.D. Ph.D
Phone +8615874179855
Email wurenrong@csu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Repetitive transcranial magnetic stimulation (rTMS) has been successfully used to help patients with treatment resistant depression. However, its role in alleviating self injuries without suicidal ideation remained uncertain. This trial will compare the effectiveness of active accelerated intermittent theta burst stimulation (aiTBS) rTMS to a placebo control on non-suicidal self injury (NSSI) in patients with unipolar disorder and bipolar disorder.


Description:

The study will evaluate the efficacy and safety of aiTBS in unipolar and bipolar depressive patients with NSSI or suicidal thoughts and behaviors by measuring changes in clinical ratings at baseline, after all the treatments, and 2 weeks, 4 weeks after treatment. 60 inpatients will be randomized to receive active or sham interventions administered to the left dorso-lateral prefrontal cortex. The treatment will apply active aiTBS rTMS involving 1800 pulses (9 minutes), 5x daily at 60 minutes intervals for 5 days. Changes in mood and sleep from baseline to the end of the study will be measured with The Hamilton Rating Scale for Depression-17 item (HAM-D17), Hamilton Anxiety Scale (HAMA), Young's Mania Scale (YMRS), and Pittsburgh Sleep Quality Index (PSQI) . Non-suicidal self injury will be assessed by the Deliberate Self-Harm Inventory (DSHI) and the Ottawa self-injury inventory (OSI). Suicidal ideation and behaviors assessments include Beck Suicidal Scale Inventory (BSI), the Ottawa self-injury inventory (OSI) and several questions from Self-Injurious Thoughts and Behaviors Interview - Revised (SITBI-R). Improvement of cognitive dysfunction could be measured by Barratt Impulsiveness Scale-11 (BIS-11), near infrared spectroscopy (fNIRS). Treatment Emergent Symptom Scale (TESS) would be used to eliminate side effects of combined drugs at baseline and the adverse event record form (AERF) will be used to appraise the safety of aiTBS treatment using these parameters. To record the change in sensitivity to pain and examine the tolerability of the treatment for these participants, visual analogue scale (VAS) is employed after completing 5 sessions treatment every day.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date February 28, 2025
Est. primary completion date February 28, 2025
Accepts healthy volunteers No
Gender All
Age group 12 Years to 18 Years
Eligibility Inclusion Criteria: 1. Documentation of DSM-5 criteria for current major depressive disorder (MDD) or bipolar disorder (BD) will be required for study entry. 2. Ages between 12 and 18 years 3. At least 1 caregivers to supervise the patient within 3 month. 4. A score of greater than 17 on the HAM-D17. 5. Occurrences of self injury behavior consistent with the DSM-5 criteria of NSSI more than 3 times in a month. 6. Willingness to participate in the study and sign informed consents Exclusion Criteria: 1. Substance abusers such as psychoactive drugs or alcohol. 2. Severe physical disability and unable to complete follow-up. 3. Comorbid other major mental illnesses that meet the DSM-5 criteria, such as schizophrenia, mental retardation, dementia, severe cognitive impairment, attention deficit hyperactivity disorder, etc. 4. Currently in a manic episode, YMRS>12; rapid-cycling bipolar disorder, bipolar disorder with mixed features. 5. Suffering from any severe physical disease, neurological disease, traumatic brain injury, etc, that affects the structure or function of the brain in the lifetime. 6. Unable to read, understand and complete the assessment or to cooperate with the investigators. 7. Any implants covering a pacemaker, metallic or magnetic objects in the body, or other conditions not suitable for rTMS. 8. A history or family history of epilepsy and other contraindications to TMS. 9. Daily use of benzodiazepines (more than 2mg/d), theophylline, stimulants such as methylphenidate, anticonvulsants, bupropion, etc. 10. Those who have received systematic psychotherapy (interpersonal relationship therapy, dynamic therapy, cognitive behavioral therapy) within 3 months before baseline. 11. Other examination abnormalities considered to be inappropriate by investigators.

Study Design


Intervention

Device:
Active iTBS
MagPro X100
Sham iTBS
MagPro X100

Locations

Country Name City State
China Mental Health Institute of Second Xiangya Hospital,CSU Changsha Hunan

Sponsors (1)

Lead Sponsor Collaborator
Central South University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other The retrospect of NSSI behavior Measured by Ottawa self-injury inventory (OSI), including reasons, addiction, site of NSSI, etc. Baseline
Other Borderline features of patients with NSSI Measured by The Borderline Personality Feature Scale for Children - 11 (BPFS-C-11) ranging from 24 to 120 Baseline
Other Child maltreatment of patients with NSSI Measured by the Childhood Trauma Questionnaire (CTQ) ranging from 25 to 125. Baseline
Other Fundelmental parental style of caregivers of patients with NSSI Measured by the Parental Bonding Instrument (PBI) containing two subscales ranging from 0 to 75 for both mother and father version. Baseline
Other Safety and tolerance of the intervention Recording any side effects in the adverse event record form (AERF). After 5 treatment days
Primary Changes in the Deliberate Self-Harm Inventory (DSHI) Containing one subscale ranging from 0 to 57 to measure the frequencies of NSSI behavior and one subscale ranging from 0 to 76 to measure the severity of NSSI behavior. Baseline, after 5 treatment days, 2 week and 4 week post-treatment
Secondary Changes in Pittsburgh Sleep Quality Index (PSQI) Range from 0-21, higher score indicates severe poorer sleep quality Baseline, after 5 treatment days, 2 week and 4 week post-treatment
Secondary Changes in Hamilton Anxiety Scale (HAMA) Range from 0-56, higher score indicates more severe symptoms Baseline, after 5 treatment days, 2 week and 4 week post-treatment
Secondary Changes in Young's Mania Scale (YMRS) Range from 0-60, higher score indicates more severe symptoms Baseline, after 5 treatment days, 2 week and 4 week post-treatment
Secondary Changes in Barratt Impulsiveness Scale-11 (BIS-11) Range from 26-104, higher score indicates higher impulsivity Baseline, after 5 treatment days, 2 week and 4 week post-treatment
Secondary Changes in cerebral blood flow of PFC through Near Infrared Spectroscopy (fNIRS) Measuring the hemoglobin concentration of cerebral cortex during resting state and verbal fluency test. Baseline, after 5 treatment days
Secondary Changes in the 17-item Hamilton Rating Scale for Depression (HAMD-17) This will be measured as both a continuous variable (scores on HAMD-17 ) and a categorical one (i.e. the response rates of >50% reduction from baseline HAMD-17 and remission rates defined as HAMD-17 <7). Baseline, after 5 treatment days, 2 week and 4 week post-treatment
Secondary Changes in Beck Suicidal Scale Inventory (BSI) Range from 0- 38, higher score indicates more severe suicide ideation. Baseline, after 5 treatment days, 2 week and 4 week post-treatment
Secondary Changes in The Clinical Global Impression (CGI) Measuring the symptom severity, overall improvement, and therapeutic response to intervention. Baseline, after 5 treatment days, 2 week and 4 week post-treatment
Secondary Changes in the subscale of addiction of NSSI from OSI (Ottawa self-injury inventory) Range from 0- 28, higher score indicates higher addiction. Baseline, after 5 treatment days, 2 week and 4 week post-treatment
Secondary Changes in number of occurrences of Non-Suicidal Self Injurious ideation Through SITBI-R The frequency of NSSI thoughts during the latest week Baseline, after 5 treatment days, 2 week and 4 week post-treatment
Secondary Changes in likelihood of future Non-Suicidal Self Injury Through SITBI-R Range from 0-4, higher score indicates more likelihood to conduct NSSI in the future Baseline, after 5 treatment days, 2 week and 4 week post-treatment
Secondary Changes in the Deliberate Self-Harm Inventory-ideation (DSHI-ideation) Range from 0 to 57 to measure the frequency of NSSI ideation Baseline, after 5 treatment days, 2 week and 4 week post-treatment
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A